NCT00244374

Brief Summary

The purpose of this study is to compare the effects of (a) immunization setting and (b) outreach worker support on young injection drug users' (IDU) adherence to a multiple dose immunization schedule with a combined hepatitis A virus (HAV) inactivated and hepatitis B virus (HBV) recombinant vaccine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
546

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2004

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2004

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

October 25, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 26, 2005

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
5.1 years until next milestone

Results Posted

Study results publicly available

July 19, 2013

Completed
Last Updated

September 30, 2013

Status Verified

July 1, 2013

Enrollment Period

3.8 years

First QC Date

October 25, 2005

Results QC Date

April 25, 2013

Last Update Submit

July 25, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Vaccine Series Completion

    The primary outcome was the completion of the four-dose vaccine series in a 12 month period.

    12 months

Secondary Outcomes (4)

  • Hepatitis B Surface Antibody Seroconversion After 3 Vaccine Doses

    12 months

  • Viral Transmission Risk Behavior Association With Travel

    Baseline

  • HIV Vaccine Trial Willingness

    Baseline

  • HIV Vaccine Trial Knowledge

    Baseline

Study Arms (4)

AIC, Hepatitis A & B vaccine

EXPERIMENTAL

Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.

Biological: Hepatitis A & B vaccineBehavioral: AIC

AIC, Outreach, Hepatitis A & B vaccine

EXPERIMENTAL

AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations

Biological: Hepatitis A & B vaccineBehavioral: OutreachBehavioral: AIC

SEP, Hepatitis A & B vaccine

EXPERIMENTAL

SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.

Biological: Hepatitis A & B vaccineBehavioral: SEP

SEP, Outreach, Hepatitis A & B vaccine

EXPERIMENTAL

Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations

Biological: Hepatitis A & B vaccineBehavioral: OutreachBehavioral: SEP

Interventions

Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects\>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine. Cohort subjects\>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.

Also known as: Twinrix, Engerix-B
AIC, Hepatitis A & B vaccineAIC, Outreach, Hepatitis A & B vaccineSEP, Hepatitis A & B vaccineSEP, Outreach, Hepatitis A & B vaccine
OutreachBEHAVIORAL

Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.

Also known as: Haight Ashbury Youth Outreach Team (HAYOT), Glide Health Services
AIC, Outreach, Hepatitis A & B vaccineSEP, Outreach, Hepatitis A & B vaccine
AICBEHAVIORAL

The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.

Also known as: Adult Immunization Clinic (AIC), San Francisco Department of Public Health (SFDPH)
AIC, Hepatitis A & B vaccineAIC, Outreach, Hepatitis A & B vaccine
SEPBEHAVIORAL

Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.

Also known as: syringe exchange, needle exchange, harm reduction, San Francisco Needle Exchange (SFNE), HIV Prevention Project (HPP)
SEP, Hepatitis A & B vaccineSEP, Outreach, Hepatitis A & B vaccine

Eligibility Criteria

Age14 Years - 29 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • age 14-29 at screening
  • injected drugs in the prior 30 days

You may not qualify if:

  • Prior positive HIV antibody test
  • Prior HBV immunization
  • participated in the screening study
  • tested negative for HIV-1 antibody and HBV markers in the screening study
  • returned for screening test results within 30 days of testing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California San Francisco Medical Cen

San Francisco, California, 94143 0939, United States

Location

Related Publications (3)

  • Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend. 2008 Jan 11;93(1-2):43-50. doi: 10.1016/j.drugalcdep.2007.08.016. Epub 2007 Nov 5.

  • Etcheverry MF, Lum PJ, Evans JL, Sanchez E, de Lazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, Page K, Joseph J. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine. 2011 Feb 24;29(10):1991-6. doi: 10.1016/j.vaccine.2010.12.043. Epub 2011 Jan 15.

  • Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat. 2008 Mar;15(3):229-36. doi: 10.1111/j.1365-2893.2007.00933.x.

Related Links

MeSH Terms

Conditions

Medication AdherenceSubstance Abuse, IntravenousRisk-TakingHepatitis AHepatitis BHepatitis C

Interventions

twinrixEngerix-BCommunity-Institutional RelationsNeedle-Exchange Programs

Condition Hierarchy (Ancestors)

Patient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehaviorSubstance-Related DisordersChemically-Induced DisordersMental DisordersHepatitis, Viral, HumanVirus DiseasesInfectionsEnterovirus InfectionsPicornaviridae InfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System DiseasesBlood-Borne InfectionsCommunicable DiseasesHepadnaviridae InfectionsDNA Virus InfectionsFlaviviridae Infections

Intervention Hierarchy (Ancestors)

Public RelationsOrganization and AdministrationHealth Services AdministrationPreventive Health ServicesHealth ServicesHealth Care Facilities Workforce and Services

Results Point of Contact

Title
Dr. Paula J. Lum
Organization
University of California, San Francisco

Study Officials

  • Paula J Lum, M.D., M.P.H.

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 25, 2005

First Posted

October 26, 2005

Study Start

August 1, 2004

Primary Completion

June 1, 2008

Study Completion

June 1, 2008

Last Updated

September 30, 2013

Results First Posted

July 19, 2013

Record last verified: 2013-07

Locations